Cell assembly, method for producing the same, kit for producing the same, and method for evaluating a compound using the cell assembly

By using a scaffold of gelatin non-woven fabric and gelatin film composed of a laminated body, combined with a culture container without hydrophilization and a dry state configuration, the problem of cells falling off in the fiber sheet scaffold material is solved, and efficient cells are achieved Inoculation and density culture and support evaluation of compound properties.

CN114729308BActive Publication Date: 2024-11-19JAPAN WOOL TEXTILE +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080079764.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-09-08
Filing Date
2020-11-17
Publication Date
2024-11-19
Estimated Expiration
2040-11-17

AI Technical Summary

Technical Problem

The cell culture scaffold material composed of existing fiber sheets is unevenly distributed due to different fiber diameters, pore sizes and dense structures during cell inoculation, which is prone to problems such as cells stay on the surface or fall off from the scaffold.

Method used

A scaffold consisting of a laminated body, including gelatin non-woven fabric with gelatin as the main component and a gelatin film laminated on the surface of gelatin non-woven fabric. The cells are present on the surface and inside of gelatin non-woven fabric and are treated without hydrophilization. In the culture vessel and the scaffold configuration in the dry state, the cell suspension was added dropwise to inhibit cell shedding.

Benefits of technology

It effectively inhibits the shedding of cells from the scaffold, improves the inoculation efficiency, and ensures high-density cell culture and evaluation of compound properties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0003646868360000091
    Figure GDA0003646868360000091
  • Figure GDA0003646868360000092
    Figure GDA0003646868360000092
  • Figure GDA0003646868360000201
    Figure GDA0003646868360000201
Patent Text Reader

Abstract

The present invention relates to a cell aggregate, characterized in that it comprises cells and a scaffold, wherein the scaffold is composed of a laminate, wherein the laminate comprises a gelatin nonwoven fabric with gelatin as the main component and a gelatin film with gelatin as the main component laminated on one surface of the gelatin nonwoven fabric, wherein the cells are present on at least one of the surface and the interior of the gelatin nonwoven fabric. The cell aggregate can be prepared by arranging a swollen scaffold in a culture container whose inner surface is in a dry state in such a way that the gelatin film contacts the inner bottom surface of the culture container, dripping a cell suspension on the gelatin nonwoven fabric of the scaffold and culturing. Thus, a cell aggregate with high inoculation efficiency in which the detachment of cells from the scaffold is suppressed, a method for manufacturing the same, a kit for manufacturing the same, and an evaluation method for a compound using the cell aggregate can be provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a cell assembly with high seeding efficiency in which cell shedding from a scaffold is suppressed, a method for producing the same, a kit for producing the same, and a method for evaluating a compound using the cell assembly. Background Art

[0002] It is known that cells interact three-dimensionally in vivo, and even outside the body, by making cells interact three-dimensionally, the function is improved. The cell culture scaffold material composed of fiber sheets provides a place for culturing cells three-dimensionally and promotes interaction, so it is expected to be used in mass cell culture, medical equipment, cell transplantation therapy, drug safety evaluation, disease models, etc. In particular, fiber sheets using biocompatible polymers are suitable for use as medical and cell culture scaffolds. For example, Patent Document 1 records that nanofibers composed of biopolymers such as gelatin, collagen and cellulose are formed on a support such as gauze or sponge and used as a culture substrate. Patent Document 2 records the use of a biocompatible long fiber non-woven fabric formed by partially melt-bonding the fiber intersections of biocompatible long fibers with an average fiber diameter of 1 to 70 μm as a cell culture scaffold.

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: International Publication No. 2014 / 196549

[0006] Patent Document 2: International Publication No. 2018 / 235745 Summary of the invention

[0007] Problems to be solved by the invention

[0008] However, it is known that when cells are inoculated in a cell culture scaffold material composed of a fiber sheet, the cell distribution changes due to differences in the fiber diameter, pore size, density, and other structures of the scaffold material. For example, in a dense scaffold, cells tend to stay on the surface layer, and there is a problem that cells surround the scaffold and fall off. On the other hand, in a sparse scaffold, although cells invade the interior, there is a problem that cells penetrate through the scaffold or leak out from the side of the scaffold and fall off.

[0009] The present invention aims to solve the above-mentioned conventional problems and provides a cell mass with high seeding efficiency in which cell shedding from a scaffold is suppressed, a method for producing the cell mass, a kit for producing the cell mass, and a method for evaluating a compound using the cell mass.

[0010] Means for solving problems

[0011] The present invention relates to a cell aggregate, characterized in that it comprises cells and a scaffold, wherein the scaffold is composed of a laminate, the laminate comprising a gelatin non-woven fabric with gelatin as the main component and a gelatin membrane with gelatin as the main component laminated on one surface of the gelatin non-woven fabric, and the cells are present on at least one of the surface and the interior of the gelatin non-woven fabric.

[0012] The present invention also relates to a method for manufacturing the above-mentioned cell aggregate, characterized in that it includes the following steps: a step of preparing a support composed of a stack and a culture container whose inner surface has not been hydrophilized, wherein the stack includes a gelatin non-woven fabric with gelatin as the main component and a gelatin film with gelatin as the main component stacked on one surface of the gelatin non-woven fabric; a step of arranging the swollen support in a culture container whose inner surface is in a dry state in a manner such that the gelatin film side is in contact with the inner bottom surface of the culture container; and a step of dripping a cell suspension onto the gelatin non-woven fabric of the support for culture.

[0013] The present invention also relates to a method for evaluating a compound for evaluating the property of the compound, comprising the steps of: bringing the compound into contact with the cell mass; and determining whether the physiological properties of the cell mass are changed by contact with the compound.

[0014] Effects of the Invention

[0015] The present invention can provide a cell aggregate with high seeding efficiency in which the detachment of cells from a scaffold is suppressed.

[0016] According to the production method of the present invention, it is possible to suppress the detachment of cells from the scaffold and to produce a cell mass with high seeding efficiency.

[0017] By using the production kit of the present invention, it is possible to suppress the detachment of cells from the scaffold and to produce a cell mass with high seeding efficiency.

[0018] The present invention can effectively evaluate the properties of a compound by using a three-dimensionally cultured cell aggregate. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a scanning electron microscope photograph (100 times magnification) of a stent (laminated body) used in one example of the present invention.

[0020] Figure 2 This is a scanning electron microscope photograph (100 times magnification) of a stent (laminate) used in another example of the present invention.

[0021] Figure 3These are images (4 times) obtained by observing the end of the scaffold using an optical microscope in Example 1. (a) is the result after cell seeding, and (b) is the result when liquid culture medium was added after 3 hours of culture.

[0022] Figure 4 These are images obtained by fluorescent observation of living cells in the scaffold in Example 1, (a) is an overall image of the scaffold after cell inoculation, (b) is an enlarged image of its central portion, (c) is an overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its central portion, (e) is an overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its central portion.

[0023] Figure 5 These are images obtained by fluorescent observation of living cells in the scaffold in Example 2, (a) is an overall image of the scaffold after cell inoculation, (b) is an enlarged image of its central portion, (c) is an overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its central portion, (e) is an overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its central portion.

[0024] Figure 6 These are images (x4) obtained by observing the ends of the scaffolds using an optical microscope in Example 3. (a) is the result after cell seeding, and (b) is the result when liquid culture medium was added after 3 hours of culture.

[0025] Figure 7 These are images obtained by fluorescent observation of living cells in the scaffold in Example 3, (a) is an overall image of the scaffold after cell inoculation, (b) is an enlarged image of its central portion, (c) is an overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its central portion, (e) is an overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its central portion.

[0026] Figure 8 These are images obtained by fluorescent observation of living cells in the scaffold in Example 4, (a) is an overall image of the scaffold after cell inoculation, (b) is an enlarged image of its center, (c) is an overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its center, (e) is an overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its center.

[0027] Fig. 9These are images (x4) of the ends of the stent observed with an optical microscope in Comparative Example 1. (a) is the result after cell seeding, and (b) is the result after culturing for 3 hours when a liquid culture medium was added.

[0028] Fig.10 These are images (x4) of the ends of the stent observed with an optical microscope in Comparative Example 2. (a) is the result after cell seeding, and (b) is the result when liquid culture medium was added after 3 hours of culture.

[0029] Fig.11 The images are obtained by observing the distribution of living cells in the scaffold after culturing for 72 hours in Example 1, (a) is the result obtained by observing the surface of the gelatin non-woven fabric side, (b) is the result of a position 100 μm away from the surface of the gelatin non-woven fabric in the thickness direction, (c) is the result of a position 200 μm away from the surface of the gelatin non-woven fabric in the thickness direction, (d) is the result of a position 200 μm away from the surface of the gelatin membrane in the thickness direction, (e) is the result of a position 100 μm away from the surface of the gelatin membrane in the thickness direction, and (f) is the result of observing the surface of the gelatin membrane side.

[0030] Fig.12 The images are obtained by observing the distribution of living cells in the scaffold after culturing for 72 hours in Example 2, (a) is the result obtained by observing the surface of the gelatin non-woven fabric side, (b) is the result of a position 100 μm away from the surface of the gelatin non-woven fabric in the thickness direction, (c) is the result of a position 200 μm away from the surface of the gelatin non-woven fabric in the thickness direction, (d) is the result of a position 200 μm away from the surface of the gelatin membrane in the thickness direction, (e) is the result of a position 100 μm away from the surface of the gelatin membrane in the thickness direction, and (f) is the result of observing the surface of the gelatin membrane side.

[0031] Fig.13 These are the results of imaging observations of calcium ions in a cell aggregate on the 4th day of culture in Example 5, (a) is a bright field image of the cell aggregate, (b) is an image obtained by fluorescence observation of calcium ions in cells at a specified time point, (c) is an image obtained by fluorescence observation of calcium ions in cells 0.7 seconds after the time point of (b), and (d) is a graph in which the fluorescence intensity of measurement point A and measurement point B is plotted against time.

[0032] Fig.14 The results show the responsiveness of the cell aggregates cultured on day 4 in Example 5 to isoproterenol.

[0033] Fig.15These are the results of imaging observation of calcium ions in a cell aggregate on the 4th day of culture in Example 6, (a) is a bright field image of the cell aggregate, (b) is an image obtained by fluorescence observation of calcium ions in the cells at a specified time point, (c) is an image obtained by fluorescence observation of calcium ions in the cells 0.7 seconds after the time point of (b), and (d) is a graph in which the fluorescence intensity of measurement point A and measurement point B is plotted against time.

[0034] Fig.16 The results of the responsiveness to E-4031 on the 4th day of culture in Example 6 are shown. (a) is an image obtained by fluorescence observation of calcium ions in cells 120 minutes after the addition of E-4031, (b) is an image obtained by fluorescence observation of calcium ions in cells 0.4 seconds after the time point of (a), and (c) is a graph in which the fluorescence intensity of measurement point A and measurement point B is plotted against time.

[0035] Fig.17 The fluorescence staining results of the cardiomyocyte aggregates in Example 7. (a) is a cell nucleus and actin filament staining image on the 3rd day of culture, (b) is an α-actin immunostaining image on the 3rd day of culture, and (c) is a partial enlarged image of (b). (d) is a cell nucleus and actin filament staining image on the 7th day of culture, (e) is an α-actin immunostaining image on the 7th day of culture, and (f) is a partial enlarged image of (e).

[0036] Fig.18 Graphs showing the responsiveness to each compound in Example 7. (a) is a signal waveform of calcium ions before and after administration of isoproterenol, and (b) is the pulse rate at each concentration of isoproterenol. (c) is a signal waveform of calcium ions before and after administration of E-4031, and (d) is the pulse rate at each concentration of E-4031. (e) is a signal waveform of calcium ions before and after administration of verapamil, and (f) is the pulse rate at each concentration of verapamil.

[0037] Fig.19 The graphs are graphs showing the responsiveness to each compound in Example 7. (a) shows the contractile force before and after administration of isoproterenol, and (b) shows the contraction and relaxation velocity before and after administration of isoproterenol. (c) shows the contractile force before and after administration of E-4031, and (d) shows the contraction and relaxation velocity before and after administration of E-4031. (e) shows the contractile force before and after administration of verapamil, and (f) shows the contraction and relaxation velocity before and after administration of verapamil.

[0038] Fig. 20The graphs show the responsiveness (signal waveform of calcium ions) to each compound in Example 8. (a) shows the results of azithromycin, (b) shows the results of chloroquine, (c) shows the results of hydroxychloroquine, (d) shows the results of azithromycin (3 μM) and chloroquine in combination, and (e) shows the results of azithromycin (3 μM) and hydroxychloroquine in combination.

[0039] Fig.21 It is a graph showing the responsiveness (contractile force) to each compound in Example 8. (a) is the result of azithromycin, (b) is the result of chloroquine, (c) is the result of hydroxychloroquine, (d) is the result of azithromycin (3 μM) and chloroquine, and (e) is the result of azithromycin (3 μM) and hydroxychloroquine.

[0040] Fig. 22 This is a graph showing the responsiveness to the compound in Example 9.

[0041] Fig.23 This is a schematic diagram of a stent manufacturing apparatus used in one embodiment of the present invention. DETAILED DESCRIPTION

[0042] The inventors of the present invention have repeatedly studied to solve the above-mentioned problems. As a result, it was found that by using a scaffold composed of a laminated body comprising a gelatin nonwoven fabric mainly composed of gelatin and a gelatin membrane mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric, and allowing cells to be present on at least one of the surface and the inside of the gelatin nonwoven fabric, preferably both, a cell aggregate with high seeding efficiency in which cell shedding from the scaffold is suppressed can be obtained.

[0043] In particular, it was found that by using a culture container (non-hydrophilic) in which the inner surface (inner bottom surface and inner side surface) of a culture container and a scaffold composed of a laminated body including a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric, the swollen scaffold is arranged in a culture container whose inner surface is in a dry state so that the gelatin film side contacts the inner bottom surface of the culture container, and a cell suspension is dripped on the gelatin nonwoven fabric of the scaffold, surprisingly, the cell suspension stays on the scaffold, inhibiting the cells from flowing out to the periphery of the scaffold, that is, the cells from falling off the scaffold are inhibited, and the seeding efficiency is improved. It is speculated that this is because the hydrophilicity (wettability) of the scaffold composed of the laminated body of the gelatin nonwoven fabric and the gelatin film exceeds the hydrophilicity (wettability) of the inner surface of the culture container, so the cell suspension does not flow from the scaffold to the culture container side, and therefore the cells do not fall off the scaffold. Furthermore, even if the cells are pre-cultured for a predetermined time while remaining inside and / or on the surface of the scaffold to promote cell adhesion, and then additional liquid culture medium is added and the scaffold is immersed in the liquid culture medium, the cells remain remaining on the scaffold and do not fall off the scaffold.

[0044] On the other hand, in the case of a (hydrophilic) culture container in which the inner surface such as the inner bottom surface of the culture container is hydrophilized to improve cell adhesion, when a cell suspension is dripped onto the scaffold, the cell suspension flows out of the scaffold to the surrounding area, and the cells fall off the scaffold.

[0045] Generally, for proliferative cells, in order to achieve high density in the scaffold, a cell proliferation period of more than one week is required. In addition, for non-proliferative cells, if the seeding efficiency is poor, it is difficult to achieve high density of cells in the scaffold. However, if the above-mentioned seeding method is used, the seeding efficiency is high and high-density seeding can be performed, so high-density culture can be performed from the initial stage of culture.

[0046] Therefore, a cell mass that has been three-dimensionally cultured at a high density from the early stage of culture can be obtained, and the properties of a compound can be evaluated efficiently by using this cell mass.

[0047] In the present invention, "swelling" means swelling to a saturated state with one or more liquids selected from water, a buffer solution or a liquid culture medium.

[0048] The gelatin nonwoven fabric and gelatin film are both composed of gelatin as the main component. In the present invention, the main component refers to gelatin containing more than 90% by mass. Other components of less than 10% by mass can be other biocompatible polymers, cross-linking agents, drugs, plasticizers, other additives, etc. as needed. It can also be substantially 100% by mass of gelatin. The scaffold of the present invention is composed of gelatin with high safety and excellent biological absorbability as the main component, so the scaffold can be transplanted into a living body and is suitable for use as a three-dimensional cell tissue required for regenerative therapy, cell research and drug development research.

[0049] The type and part of the animal from which the collagen as the raw material of the gelatin is derived are not particularly limited. Collagen can be derived from vertebrates or fish, for example. In addition, collagen derived from various organs or tissues such as dermis, ligaments, tendons, bones, and cartilage can be appropriately used. In addition, the method for preparing gelatin from collagen is not particularly limited, and examples thereof include acid treatment, alkali treatment, and enzyme treatment. The molecular weight of the gelatin is not particularly limited, and gelatin of various molecular weights can be appropriately selected and used. In addition, one type of gelatin can be used, or two or more types can be used in combination.

[0050] The gelatin is not particularly limited, but from the viewpoint of having appropriate softness and hardness and improving the operability of the stent, the gelatin strength is preferably 100 g or more and 400 g or less, and more preferably 150 g or more and 360 g or less. In the present invention, the gelatin strength is measured according to JIS K 6503. The gelatin may be a commercially available product.

[0051] As the above-mentioned other biocompatible polymers, there are no particular limitations, and for example, natural polymers and synthetic polymers can be used. As natural polymers, for example, proteins and polysaccharides can be cited. As proteins, for example, collagen, fibronectin, fibrinogen, laminin, fibrin, etc. can be cited. As polysaccharides, for example, natural polymers such as chitosan, calcium alginate, heparan sulfate, chondroitin sulfate, hyaluronic acid, heparin, starch, gellan gum, agarose, guar gum, xanthan gum, carrageenan, pectin, locust bean gum, tamarind gum, diutan gum can be used, and derivatives of natural polymers such as carboxymethyl cellulose can also be used. Examples of synthetic polymers include non-absorbent synthetic polymers such as polyethylene glycol, polyethylene terephthalate, polyvinyl alcohol, thermoplastic elastomers, polypropylene, polyethylene, polystyrene, polymethyl methacrylate, polycarbonate, polydimethylsiloxane, cycloolefin polymers, and amorphous fluororesins, and bioabsorbable polymers such as polylactic acid, polyglycolic acid, polycaprolactone, and polydioxetane. The above-mentioned other biocompatible polymers may be used alone or in combination of two or more.

[0052] The average fiber diameter of the gelatin fibers constituting the gelatin nonwoven fabric after swelling is preferably greater than 2 μm and less than 400 μm, more preferably greater than 5 μm and less than 200 μm, further preferably greater than 10 μm and less than 100 μm, and particularly preferably greater than 15 μm and less than 45 μm. If the average fiber diameter of the gelatin fibers is within the above range, when cells are seeded on the surface of the gelatin nonwoven fabric of the scaffold, the cells can easily invade the scaffold and can be evenly distributed inside the scaffold. In the present invention, the "average fiber diameter after swelling" refers to the average value of the diameters of 50 fibers arbitrarily selected from the gelatin nonwoven fabric in the swollen scaffold.

[0053] The fiber intersections of the gelatin fibers constituting the gelatin nonwoven fabric are preferably partially melt-bonded. This partial melt-bonding is not particularly limited, and for example, as described later, can be performed by piling up gelatin fibers in an incompletely solidified state that are blown away by a pressure fluid during the manufacture of the stent. Through this partial melt-bonding, the gelatin nonwoven fabric becomes a bridging structure, which is easy to form into a desired shape, and the forming stability is also high. In addition, by partially melt-bonding the fiber intersections, the gelatin nonwoven fabric will not become weak even if it is wetted with water. In addition, in the gelatin nonwoven fabric, a portion of the fiber intersections may be melt-bonded, or all of the fiber intersections may be melt-bonded.

[0054] The gelatin nonwoven fabric is not particularly limited, and for example, from the viewpoint of improving operability and cell invasiveness, the thickness is preferably 0.1 mm or more, more preferably 0.2 mm or more, further preferably 0.3 mm or more, and particularly preferably 0.4 mm or more. In addition, the gelatin nonwoven fabric is not particularly limited, and for example, from the viewpoint of improving cell survival rate in three-dimensional culture, the thickness is preferably 2 mm or less, more preferably 1.5 mm or less, further preferably 1 mm or less, and particularly preferably 0.7 mm or less.

[0055] The gelatin nonwoven fabric is not particularly limited. For example, from the viewpoint of inhibiting cell shedding, the weight per unit area is preferably 10 g / m 2 More preferably 25g / m 2 More preferably, 50 g / m 2 In addition, the gelatin nonwoven fabric is not particularly limited, and for example, from the viewpoint of improving cell invasiveness and cell survival rate in three-dimensional culture, the weight per unit area is preferably 600 g / m 2 Below, more preferably 500g / m 2 Below, more preferably 400g / m 2 the following.

[0056] The gelatin nonwoven fabric is not particularly limited. For example, from the perspective of improving the invasiveness of cells and the survival rate of cells in three-dimensional culture, the pore diameter is preferably 20 μm or more, more preferably 30 μm or more, and further preferably 40 μm or more. In addition, the gelatin nonwoven fabric is not particularly limited. For example, from the perspective of inhibiting cell shedding, the pore diameter is preferably 250 μm or less, more preferably 200 μm or less, and further preferably 180 μm or less. In the present invention, the pore diameter of the gelatin nonwoven fabric can be calculated based on Wrotnowski's assumption by the following calculation formula (1).

[0057] [Mathematical formula 1]

[0058] [Calculation formula 1]

[0059]

[0060]

[0061] D: Pore diameter (μm)

[0062] W: non-woven fabric apparent density (g / cm 3 )

[0063] F: Fineness (d)

[0064] f: fiber diameter (μm)

[0065] ρ: Fiber density (g / cm 3 )

[0066] Preferably, the gelatin film is disposed on one surface of the gelatin nonwoven fabric and is partially melt-bonded with the gelatin fibers constituting the gelatin nonwoven fabric. The partial melt-bonding is not particularly limited, and for example, as described later, it can be achieved by depositing gelatin fibers in an incompletely solidified state that are blown away by a pressure fluid during the manufacture of the scaffold on the gelatin film. Through the partial melt-bonding, the gelatin nonwoven fabric and the gelatin film are integrated, and cells are inhibited from penetrating through the scaffold and falling off from the cells. In addition, by integrating the gelatin nonwoven fabric with the gelatin film, it is easy to peel off the cell aggregate from the culture container, and there is less damage to the cells, thereby improving the implantability at the transplant site.

[0067] As an example, from the viewpoint of simplicity and operability, the thickness of the gelatin film is preferably 0.5 μm or more, more preferably 0.6 μm or more, further preferably 0.7 μm or more, and particularly preferably 0.8 μm or more. In addition, as an example, from the viewpoint of improving the integrity with the gelatin nonwoven fabric and the efficiency of three-dimensional cell culture, the thickness of the gelatin film is preferably 10 μm or less, more preferably 8 μm or less, further preferably 6 μm or less, further preferably 4 μm or less, and particularly preferably 2 μm or less.

[0068] The gelatin membrane is preferably a non-porous membrane, but may have micropores of a size that prevents cells from penetrating, for example, micropores with a diameter of about 10 μm or less or 5 μm or less.

[0069] The ratio Tf / Tn of the thickness Tn of the gelatin nonwoven fabric to the thickness Tf of the gelatin film is preferably 7.5×10 -3 As a result, the warping of the swollen laminate is suppressed, and the cell suspension is more likely to stay on the scaffold. In addition, even when the laminate swells, the gelatin film easily follows the gelatin nonwoven fabric and is less likely to be peeled off or damaged. The Tf / Tn is more preferably 7.0×10 -3 Below, more preferably 6.0×10 -3 In addition, from the viewpoint of easily suppressing the peeling and destruction of the gelatin film, the Tf / Tn is preferably 1.0×10 -3 More preferably, 1.5×10 -3 above.

[0070] The laminate is not particularly limited. For example, from the viewpoint of maintaining strength during cell culture and improving the survival rate of cells in three-dimensional culture, the compression deformation rate at a compressive stress of 1.0 kPa after swelling with water to a saturated state (hereinafter also referred to as "compression deformation rate") is preferably 40% or less, more preferably 35% or less, and further preferably 30% or less. The saturated state refers to a state in which water is contained to a maximum limit, and is a state in which the water content remains at a certain limit and does not increase further. In this specification, in a laminate after swelling with water to a saturated state, when the thickness at no load is recorded as (H1) and the thickness at a compressive stress of 1.0 kPa is recorded as (H2), the compression deformation rate can be calculated by the following formula. The compression test is carried out as described later.

[0071] Compression deformation rate (%) = 100-{(H2 / H1)×100}

[0072] From the viewpoint of easily maintaining the morphology during cell culture and efficiently performing three-dimensional cell culture, the gelatin nonwoven fabric and the gelatin film are preferably cross-linked. Specifically, the cross-linking can be performed as described below.

[0073] In one or more embodiments of the present invention, the laminate of the gelatin nonwoven fabric and the gelatin film can be coated with cell adhesion factors, cell induction factors, cell growth factors, substances that give nutrition and energy to cells, substances that inhibit or enhance cell functions, etc. As cell adhesion factors, there is no particular limitation, and for example, fibronectin, etc. can be cited. By coating the laminate with cell adhesion factors, cells become more likely to stay on the support. As substances that give nutrition and energy to cells, there is no particular limitation, and for example, ATP, pyruvic acid, glutamine, etc. can be cited. In addition, in one or more embodiments of the present invention, the laminate of the gelatin nonwoven fabric and the gelatin film can also be immersed in a solution containing physiologically active substances such as cell induction factors and cell growth factors, so that it contains these components. During cell culture, these physiologically active substances are slowly released from the laminate, thereby promoting cell culture.

[0074] The support is not particularly limited, but from the viewpoint of suppressing the generation of impurities, preventing product contamination, and integrating the gelatin non-woven fabric and the gelatin film without using adhesive components or hot pressing mechanisms, it is preferably made as follows: a spinning solution containing gelatin is extruded from a nozzle outlet into the air, and a pressure fluid is ejected toward the front from a fluid ejection port located behind the nozzle outlet and in a non-contact state with the nozzle outlet, so that the extruded spinning solution is formed into fibers along with the pressure fluid, and the fibers obtained by the fiber formation are aggregated on a gelatin film having gelatin as the main component to form a gelatin non-woven fabric, thereby obtaining a laminate of the gelatin film and the gelatin non-woven fabric.

[0075] The gelatin film is not particularly limited and can be made by a known film manufacturing method. For example, it can be made by applying a gelatin solution to a substrate surface and then drying it. As the substrate, for example, a polyethylene terephthalate film (PET film), a glass plate, a polystyrene sheet, a fluororesin sheet, etc. can be used. The PET film, the glass plate, the polystyrene sheet, the fluororesin sheet, etc. can also be waterproofed.

[0076] The gelatin solution can be obtained by dissolving gelatin alone or, as required, gelatin and other biocompatible polymers that can be used as the other components in a solvent. As the solvent, for example, alcohols such as water, ethanol, 1-propanol, 2-propanol, glycerol, or amides such as dimethylformamide and dimethylacetamide can be cited. These solvents can be used alone or in combination of two or more. Among them, from the viewpoint of handleability, it is preferred to use water such as distilled water, pure water, ultrapure water, ion exchange water. By making gelatin water-soluble, it can be used for membrane in the state of aqueous solution, and the safety of the organism becomes higher.

[0077] The concentration of gelatin is not particularly limited. For example, from the viewpoint of film-forming property and castability, when the gelatin solution is set to 100% by mass, it is preferably 0.1% by mass or more and 35% by mass or less, more preferably 1% by mass or more and 30% by mass or less, and further preferably 3% by mass or more and 20% by mass or less. The dissolution temperature (temperature of the solvent) is preferably 10°C or more and 90°C or less, more preferably 20°C or more and 80°C or less, and further preferably 30°C or more and 70°C or less. As needed, after dissolving the gelatin in the solvent, it can be filtered to remove foreign matter, garbage, etc. In addition, as needed, it is also possible to remove dissolved air by decompression or vacuum degassing. From the viewpoint of efficiently removing gas (bubbles), the vacuum degree during decompression degassing is preferably 5kPa or more and 30kPa or less.

[0078] The drying is not particularly limited, and can be performed, for example, by natural drying, heating drying, reduced pressure drying (vacuum drying), forced exhaust drying, forced circulation convection, etc. Specifically, the drying temperature can be, for example, -40°C or higher and 90°C or lower, 0°C or higher and 60°C or lower, or 10°C or higher and 40°C or lower. In addition, the drying time can be, for example, in the range of 1 hour or higher and 200 hours or lower, preferably in the range of 3 hours or higher and 100 hours or lower, and more preferably in the range of 5 hours or higher and 48 hours or lower.

[0079] In the meltblowing method, since the spinning solution containing gelatin is extruded from the nozzle outlet, a pressure fluid is ejected toward the front from a fluid ejection port located behind the nozzle outlet and in a non-contact state with the nozzle outlet, so that the extruded spinning solution is directly fiberized in a dry manner along with the pressure fluid, and the obtained gelatin fibers are gathered on the gelatin film to form a non-woven fabric, thereby preventing the generation of pollutants (impurities) and enabling hygienic manufacturing. After spinning, when the fibers are gathered (stacked), the fibers are stacked on each other in a state containing water, so that the fibers are melt-bonded or entangled with each other to be integrated, and the gelatin fibers constituting the non-woven fabric are melt-bonded to the gelatin film to integrate the gelatin non-woven fabric with the gelatin film. By changing the capture distance when the fibers are stacked, the density of the non-woven fabric can be easily changed.

[0080] Fig.23 1 is a schematic diagram of a stent manufacturing apparatus used in one embodiment of the present invention. In the stent manufacturing apparatus 20, a spinning solution 2 containing gelatin placed in a heating tank 1 is extruded into the air from a nozzle outlet 3. A compressor 4 applies a predetermined pressure to the heating tank 1. 12 is a heat-insulating container.

[0081] In addition, pressure fluid 7 is ejected forward from fluid ejection port 5 located behind nozzle outlet 3 and in non-contact with nozzle outlet 3. Pressure fluid (e.g., compressed air) is supplied to fluid ejection port 5 from compressor 6. The distance between fluid ejection port 5 and nozzle outlet 3 is preferably 5 to 30 mm.

[0082] The extruded spinning solution is accompanied by the pressure fluid 7 to become gelatin fibers 8, and is deposited on the gelatin film 10 disposed on the winding roller 11 to become a gelatin nonwoven fabric 9. At this time, since the deposited fibers contain water or are not completely solidified, the fibers that are in contact at least at a part of the intersection of the fibers are melt-bonded to each other, and the gelatin fibers constituting the nonwoven fabric are melt-bonded to the gelatin film, thereby integrating the gelatin nonwoven fabric with the gelatin film. In this case, other collecting mechanisms such as a net may be used instead of the winding roller.

[0083] First, gelatin is dissolved in a solvent, preferably water, alone or as needed, with gelatin and other biocompatible polymers that can be used as other components to prepare a spinning solution. The dissolution temperature (temperature of a solvent such as water) is preferably above 20°C and below 90°C, more preferably above 40°C and below 90°C. As needed, after gelatin is dissolved in a solvent such as water, it can be filtered to remove foreign matter, garbage, etc. In addition, as needed, it is also possible to remove dissolved air by decompression or vacuum degassing. From the viewpoint of efficiently removing gas (bubbles), the vacuum degree during decompression degassing is preferably above 5kPa and below 30kPa. By making gelatin water-soluble, a spinning solution can be made and spun in the state of an aqueous solution, which increases the safety of the organism. As water, for example, pure water, distilled water, ultrapure water, etc. can be appropriately used. It should be noted that when other biocompatible water-soluble polymers are used as other components, a spinning solution can be prepared by dissolving them in water simultaneously with gelatin.

[0084] The temperature of the spinning solution is preferably above 20°C and below 90°C, more preferably above 40°C and below 90°C. If it is within the above range, gelatin can maintain a stable sol state. In addition, when the gelatin aqueous solution is set to 100 mass%, the gelatin concentration of the gelatin aqueous solution is preferably above 30 mass% and below 55 mass%. A more preferred concentration is above 35 mass% and below 50 mass%. If it is the above concentration, a stable sol state can be maintained. The viscosity of the gelatin aqueous solution (spinning solution) is preferably above 500mPa·s and below 3000mPa·s. If the viscosity of the gelatin aqueous solution is within the above range, stable spinning can be performed.

[0085] The spinning solution is ejected from a nozzle of a spinning machine, and a pressure fluid is supplied from around the nozzle, so that the ejected gelatin aqueous solution is formed into fibers along with the pressure fluid, and the obtained gelatin fibers are gathered on a gelatin film to form a gelatin nonwoven fabric. The ejection pressure of the nozzle is not particularly limited, and can be, for example, 0.1 MPa or more and 1 MPa or less.

[0086] The temperature of the pressure fluid is preferably 20°C to 120°C, more preferably 80°C to 120°C. Although it also depends on the flow rate of the pressure fluid and the temperature of the surrounding atmosphere, stable spinning can be performed as long as it is within the above temperature range. Air is preferably used as the pressure fluid, and the pressure is preferably 0.1MPa to 1MPa. If it is within the above range, the spinning solution extruded from the nozzle outlet into the air can be blown away and fiberized.

[0087] By appropriately adjusting the nozzle diameter (inner diameter) and the like, the gelatin nonwoven fabric having a desired average fiber diameter can be obtained.

[0088] The laminate of the gelatin nonwoven fabric and the gelatin film is preferably cross-linked. Thereby, the morphological stability and water resistance can be improved. The cross-linking may be a chemical cross-linking using a compound such as a cross-linking agent, but from the viewpoint of biosafety, it is preferably a cross-linking using a cross-linking agent with biosafety or a cross-linking without a cross-linking agent. As cross-linking without a cross-linking agent, for example, thermal cross-linking, electron beam cross-linking, radiation cross-linking such as gamma rays, ultraviolet cross-linking, etc. can be cited. In the case of electron beam irradiation, gamma ray irradiation, etc., sterilization and cross-linking can also be performed simultaneously. From the viewpoint of easily and simply obtaining the desired cross-linking effect, thermal cross-linking is preferred, and thermal dehydration cross-linking is more preferred. Thermal dehydration cross-linking can be performed, for example, at a temperature above 100°C and below 160°C for more than 24 hours and less than 96 hours. In addition, thermal dehydration cross-linking can be performed, for example, under a vacuum below 1 kPa. The laminate can be dried before cross-linking. Drying can be air-drying at room temperature or vacuum freeze-drying.

[0089] The laminate formed by integrating gelatin nonwoven fabric and gelatin film can be cut into a specified shape and size as needed for use as a stent. Gelatin has biocompatibility and biodegradability, so the laminate formed by integrating gelatin nonwoven fabric and gelatin film is suitable for medical or cell culture stents. The stent can be sterilized by ethylene oxide gas sterilization, water vapor (autoclave), electron beam irradiation, gamma ray and other radiation irradiation, or sterilized by ethanol treatment, etc. In the case of electron beam irradiation, gamma ray and other radiation irradiation, cross-linking can also be performed simultaneously with sterilization.

[0090] The manufacturing process of the gelatin film and laminate is preferably carried out aseptically in a clean bench or clean room. It is possible to prevent the gelatin film and laminate from being contaminated by the growth of bacteria during the operation. The manufacturing apparatus used is preferably an apparatus sterilized by autoclave, electron beam irradiation, irradiation with radiation such as gamma rays, etc. In addition, the gelatin solution is also preferably supplied to the membrane manufacturing process after being sterilized by filtration using a conventionally known filter.

[0091] In the present invention, as an example, the cross-linked laminate is punched out into a predetermined shape to form a stent, or swollen with water, a buffer solution or a predetermined liquid culture medium to form a target stent.

[0092] In one or more embodiments of the present invention, the cell aggregate comprises a scaffold and cells, and the cells are present in at least one of the surface and the interior of the gelatin nonwoven fabric, but preferably the cells are present in both the surface and the interior of the gelatin nonwoven fabric. In the case of a three-dimensional cultured cell cluster in which cells are three-dimensionally configured in this way, it can be used as a tissue. In one or more embodiments of the present invention, the cell aggregate can be formed into various shapes such as sheets and blocks as needed. In addition, the cell aggregate can be a structure of more than two layers, each layer comprising a scaffold and cells, and the cells are present in at least one of the surface and the interior of the gelatin nonwoven fabric, preferably in both.

[0093] In one or more embodiments of the present invention, the cell can be an animal cell, and its source is not particularly limited. The animal may be a human or an animal other than a human. Examples of animals other than humans include primates such as monkeys and chimpanzees; rodents such as mice, rats, and hamsters; ungulates such as cattle, sheep, goats, and pigs. In addition, in the present invention, cells include individual cells, cell lines, cells obtained by culture such as primary culture, and the like. The cells are not particularly limited, and examples thereof include somatic cells, stem cells, precursor cells, germ cells, immune cells, and the like.

[0094] Somatic cells include somatic cells constituting an organism and cancer cells derived from somatic cells. Somatic cells constituting an organism are not particularly limited, and examples thereof include fibroblasts, myocytes, endothelial cells, osteoblasts, bladder cells, lung cells, osteocytes, nerve cells, hepatocytes, chondrocytes, epithelial cells, and mesothelial cells. Cancer cells are not particularly limited, and examples thereof include breast cancer cells, renal cancer cells, prostate cancer cells, lung cancer cells, liver cancer cells, cervical cancer cells, esophageal epithelial cancer, pancreatic cancer, colorectal cancer, and bladder cancer.

[0095] Stem cells are cells that have the possibility of differentiating into various specialized cell types. Stem cells are not particularly limited, and examples thereof include embryonic stem cells (ES cells), embryonic carcinoma cells (EC), embryonic germ stem cells (EG), artificial pluripotent stem cells (iPS cells), adult stem cells, blastocyst-derived stem cells, genital ridge-derived stem cells, teratoma-derived stem cells, oncostatin-independent stem cells (OISC), bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, amniotic fluid-derived mesenchymal stem cells, skin-derived mesenchymal stem cells, and periosteum-derived mesenchymal stem cells.

[0096] Precursor cells are cells that are capable of being generated from the stem cells and differentiated into terminally differentiated cells constituting an organism.

[0097] Examples of reproductive cells include sperm, sperm cells, ovum, and egg cells.

[0098] The immune cells are not particularly limited, and examples thereof include macrophages, lymphocytes, dendritic cells, and the like.

[0099] The above-mentioned cells may be used alone or in combination of two or more kinds depending on the purpose, etc. For example, the cells are preferably selected from stem cells, cancer cells, myocardial cells, nerve cells, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from stem cells, and myocardial cells, nerve cells, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from organisms.

[0100] In one or more embodiments of the present invention, without particular limitation, the cell aggregate can be prepared as follows: a swollen scaffold is arranged in a culture container whose inner surface is dry in such a way that the gelatin film side contacts the inner bottom surface of the culture container, a cell suspension is dripped onto the gelatin nonwoven fabric of the scaffold, and the cells are inoculated and then cultured. Thus, it is possible to inhibit the cells from falling off the scaffold, improve the inoculation efficiency, and preferably culture the cells at a high density from the initial stage of the culture. Specifically, the configuration of the scaffold can be performed by clamping the ends of the scaffold with tweezers.

[0101] In one or more embodiments of the present invention, a cell inoculation method for inoculating cells on a scaffold can be provided, characterized in that a scaffold composed of a laminate and a culture container whose inner surface is not hydrophilized are prepared, the laminate comprising a gelatin non-woven fabric with gelatin as the main component and a gelatin film with gelatin as the main component laminated on one surface of the gelatin non-woven fabric, the swollen scaffold is configured in a culture container whose inner surface is in a dry state in such a way that the gelatin film side contacts the inner bottom surface of the culture container, and a cell suspension is dripped onto the gelatin non-woven fabric of the scaffold. By this cell inoculation method, cells can be inhibited from falling off the scaffold and the inoculation efficiency is improved. In one or more embodiments of the present invention, a cell culture method can be provided, in which, in the cell inoculation method, a cell suspension is dripped onto the gelatin non-woven fabric of the scaffold and left to stand for a specified time, and then a liquid culture medium is added for cell culture. By this cell culture method, cells can be cultured at a high density from the initial stage of culture.

[0102] In one or more embodiments of the present invention, the culture container is not particularly limited as long as the inner surface of the container that contacts the cell culture support and the liquid culture medium is not hydrophilized. For example, a culture dish, a plate, and a flask can be used appropriately. Specifically, an untreated (cell non-adhesive) culture dish that has not been treated to improve cell adhesion (adhesion) can be used, and a culture dish for suspension culture can be preferably used. For example, commercial products such as "IWAKI suspension culture microplate (no surface treatment) 6 holes" and "Corning nonTrement plate 6 holes" can be used.

[0103] The cell suspension can be a suspension obtained by suspending cells in a liquid culture medium. The amount of the cell suspension per unit surface area of ​​the scaffold (the amount added) can be appropriately determined according to the thickness of the scaffold, the weight per unit area, the concentration of the cell suspension, etc., and is not particularly limited, but is preferably 0.1 μL / mm 2 Above and 0.6μL / mm 2 Below, more preferably 0.2 μL / mm 2 Above and 0.5μL / mm 2 Below, more preferably 0.3 μL / mm 2 Above and 0.4μL / mm 2 When it is within the above range, the cell suspension can easily reach the inside of the scaffold evenly, and the cell suspension can easily be retained in the scaffold.

[0104] The cell seeding amount per unit surface area of ​​the scaffold is not particularly limited and can be appropriately determined based on the cell type, scaffold thickness, and unit weight. For example, from the perspective of high-density seeding, 200 cells / mm is preferred. 2 Above and 20,000 cells / mm2 Below, more preferably 2000 cells / mm 2 Above and 15000 cells / mm 2 Below, more preferably 4000 cells / mm 2 Above and 12000 cells / mm 2 the following.

[0105] The liquid culture medium is not particularly limited, and a liquid culture medium containing components required for the survival and growth of the cells can be appropriately used according to the type of cells. The culture medium can contain serum, antibiotics, growth factors, etc. Serum, for example, can be appropriately used bovine serum, fetal bovine serum, horse serum, human serum, etc. Antibiotics can be appropriately used penicillin, streptomycin, gentamicin, amphotericin, ampicillin, minomycin, kanamycin, etc. Growth factors can be appropriately used cell growth factors, differentiation inducing factors, cell adhesion factors, etc.

[0106] In one or more embodiments of the present invention, a cell suspension is added to the gelatin nonwoven fabric of the scaffold, and then allowed to stand for a predetermined time, for example, 3 to 4 hours, and pre-cultured to allow cells to adhere to the gelatin nonwoven fabric (scaffold) is performed, and then liquid culture medium is added for cell culture.

[0107] The culture may be performed at, for example, 27° C. to 40° C., or 31° C. to 37° C. The carbon dioxide content may be in the range of 2% to 10%.

[0108] The culture time can be appropriately determined according to the cell type, cell number, etc., and can be, for example, continued for 2 to 21 days, 3 to 14 days, or 4 to 10 days. The culture medium can be replaced every 2 to 4 days.

[0109] As an example, after confirming that the cells adhere to the scaffold 3 to 4 hours after cell inoculation, a liquid culture medium can be added to the culture container and cultured statically in an incubator under specified conditions (e.g., temperature 37°C, 5% CO2). The liquid culture medium can be replaced every 2 to 4 days. Alternatively, after the cells are inoculated, a liquid culture medium can be added to the culture container, and the liquid culture medium can be stirred and circulated on a magnetic stirrer placed in an incubator at 37°C and 5% CO2 while stirring and culturing. Half of the liquid culture medium can be removed every 3 to 4 days, and an equal amount of new liquid culture medium can be added to replace the culture medium. Alternatively, after the cells are inoculated, a liquid culture medium can be added to the culture container, and cultured while shaking in an incubator at 37°C and 5% CO2. Half of the liquid culture medium can also be removed every 3 to 4 days, and an equal amount of new liquid culture medium can be added to replace the culture medium. The scaffold of the present invention becomes transparent when wetted with water, so the inside of the scaffold can be observed in the culture fluid using an inverted microscope.

[0110] By seeding cells in the scaffold as described above, the seeding efficiency can be improved and high-density seeding can be performed. By culturing the cells after seeding, high-density culture can be performed.

[0111] In one or more embodiments, the present invention provides a kit for preparing a cell assembly, which comprises a scaffold composed of a laminate, and a culture container whose inner surface is not hydrophilized, wherein the laminate comprises the gelatin nonwoven fabric with gelatin as the main component and a gelatin film with gelatin as the main component laminated on one surface of the gelatin nonwoven fabric. When preparing the cell assembly, the swollen scaffold is arranged in a culture container whose inner surface is dry in such a manner that the gelatin film side contacts the inner bottom surface of the culture container, and a cell suspension is dripped onto the gelatin nonwoven fabric of the scaffold. The kit for preparing the cell assembly as described above can also be used as a cell seeding kit or a cell culture kit.

[0112] In one or more embodiments of the present invention, when the cardiomyocytes are stem cells or cardiomyocytes differentiated from somatic cells directly recombined by genes, the scaffold can promote the maturation of cardiomyocytes, and mature cardiomyocytes and cell aggregates of cardiomyocytes can be obtained. In one or more preferred embodiments of the present invention, when cardiomyocytes are present on gelatin fibers constituting the scaffold (gelatin nonwoven fabric), the area in which the cells can stretch in the length direction of the fiber is larger than that in the diameter direction of the fiber, so the cells attached to the gelatin fibers are oriented in the length direction of the fiber, and the gelatin nonwoven fabric is soft and has excellent deformation recovery, so the gelatin fibers can contract and relax together with the cardiomyocytes, thereby imparting mechanical stimulation to the cardiomyocytes and promoting the maturation of the cardiomyocytes.

[0113] In the case of cardiomyocytes differentiated from stem cells or somatic cells directly recombined by genes, they may not function fully compared to cardiomyocytes of living organisms due to immaturity. In the case of immature cardiomyocytes, in the detection of side effects of compounds, ion channels related to the prediction of arrhythmia, sarcomere structure development related to cardiac contraction disorders, and contraction enhancement effects (positive inotropic effects) when drugs are added may not be shown.

[0114] As a method for promoting the maturation of cardiomyocytes, it is known to apply external stimulation such as stretching stimulation and electrical stimulation to cardiomyocytes, but it requires the use of special culture dishes. In one or more preferred embodiments of the present invention, even if the cardiomyocytes are cardiomyocytes differentiated from stem cells or somatic cells directly recombined by genes, a cell aggregate of mature cardiomyocytes can be obtained without using special culture dishes.

[0115] As the characteristics of mature cardiomyocytes, for example, the characteristics of the structure, contractility, electrophysiology, calcium processing and metabolism of cardiomyocytes can be cited. As the structural characteristics of mature cardiomyocytes, the size becomes larger, the cell shape becomes longer, the sarcomere structure is oriented, and the sarcomere length is 1.8μm to 2.2μm. As the contractile characteristics of mature cardiomyocytes, the contractile force is increased, the α-MHC / β-MHC is increased, the titin N2A changes to titin N2B, the contractile force is increased by β-receptor stimulation, and the contractile force is increased by protein kinase A. As the electrophysiological characteristics of mature cardiomyocytes, the excitation rate is increased, the resting membrane potential is reduced, and the duration of the action potential is prolonged. As the calcium processing characteristics of mature cardiomyocytes, the calcium storage of the endoplasmic reticulum is increased, the calcium cycle is increased by adrenaline stimulation, and the development of T tubes can be cited. As the metabolic characteristics of mature cardiomyocytes, fatty acid utilization and the number of mitochondria can be increased. The characteristics of the mature cardiomyocytes can be confirmed by imaging measurement, contractile force measurement, contractile speed, pharmacological evaluation, gene analysis, etc.

[0116] As genes expressed in mature cardiomyocytes, as genes related to electrophysiology, for example, SCN5A, KCNJ2, GJA1, and CN4 can be mentioned; as genes related to calcium processing, for example, ATP2A2, CACNA1C, RYR2, SLC8A1, PLN, BIN1, and JPH2 can be mentioned; as genes related to contraction, for example, MYH7, MYH6, MYL2, TNNI3, PLN, SERCA2A can be mentioned; as genes related to metabolism, for example, CPT1B, PGC1A, and TFAM can be mentioned.

[0117] In one or more embodiments of the present invention, the cell aggregate can be applied to cell transplantation therapy, safety evaluation of compounds, toxicity evaluation of compounds, medical devices, disease models, drug development research using disease models, and the like.

[0118] In one or more embodiments of the present invention, for example, a cell assembly can be used in a method for evaluating a compound for evaluating the properties of the compound. Specifically, by contacting the compound with the cell assembly, it is determined whether the physiological properties of the cell assembly are changed due to contact with the compound, and the properties of the compound can be evaluated. The properties of the compound are not particularly limited, and may be, for example, metabolism, pharmacological action, and toxic action. More specifically, as described above, after cells are inoculated in a scaffold and cultured for a predetermined time to obtain a cell assembly, a target compound is added to the liquid culture medium used for cell culture, and after adding the compound, it is observed and evaluated whether the physiological properties of the cell assembly are changed.

[0119] In the case where the cells are cardiomyocytes, the cell aggregate can be used to evaluate the effects on the electrophysiological properties of the target compound, cardiac contraction, etc., such as arrhythmogenic risk assessment, cardiac contraction disorder, and cardiotoxicity assessment. In one or more preferred embodiments of the present invention, cardiomyocytes are present on the surface and inside of the scaffold and adhered to the scaffold (specifically, the surface of the gelatin non-woven fabric side of the gelatin fiber and gelatin membrane), that is, a three-dimensionally cultured cell aggregate in which cardiomyocytes are three-dimensionally arranged. When the cardiomyocytes contract, the cell aggregate is easy to follow the action of the cardiomyocytes as a whole, and the functionality of the cardiomyocytes such as heartbeat, action potential, and contraction behavior can be effectively evaluated. Specifically, the action potential of the cell aggregate can be evaluated by imaging of calcium ions in the cell, imaging of the membrane potential of the cell, a microelectrode array, etc., and the contraction behavior can be evaluated by observing the action of the scaffold and the fibers constituting the scaffold, and bright field, calcium ion imaging, membrane potential imaging, etc. can be freely used.

[0120] Example

[0121] Hereinafter, the present invention will be described in more detail using examples. It should be noted that the present invention is not limited to the following examples.

[0122] The measurement and evaluation methods are as follows.

[0123] <Average fiber diameter>

[0124] The swollen stent was observed using a microscope (CQ1, Yokogawa Electric Corporation), and 50 fibers selected at random were used to measure the average fiber diameter after swelling.

[0125] <Thickness>

[0126] The cross-section of the stack (bracket) was observed using a scanning electron microscope (FlexSEM1000 manufactured by Hitachi High Technologies, 100x and 500x), and the thickness of the gelatin film layer, the thickness of the gelatin nonwoven fabric, and the thickness of the stack were measured at 10 points randomly selected from the obtained scanning electron microscope photographs, and the average value was calculated.

[0127] The thickness of the swollen laminate (stent) was measured using a digital vernier caliper manufactured by Mitutoyo Corporation.

[0128] <Weight per unit area (mass per unit area)>

[0129] The basis weight of the gelatin nonwoven fabric is measured in accordance with JIS L 1913.

[0130] <Apparent density>

[0131] The density of the gelatin nonwoven fabric was calculated based on the thickness and weight per unit area of ​​the nonwoven fabric.

[0132] <Pore diameter>

[0133] The pore diameter of the gelatin nonwoven fabric was calculated by the following calculation formula 1 based on Wrotnowski's assumption.

[0134] [Mathematical formula 2]

[0135] [Calculation formula 1]

[0136]

[0137]

[0138] D: Pore diameter (μm)

[0139] W: non-woven fabric apparent density (g / cm 3 )

[0140] F: Fineness (d)

[0141] f: fiber diameter (μm)

[0142] ρ: Fiber density (g / cm 3 )

[0143] (Example 1)

[0144] <Preparation of laminate (scaffold)>

[0145] As gelatin, gelatin manufactured by Nitta Gelatin Co., Ltd. (gelatin strength 262 g, raw material: alkali-treated bovine bone) was used, and gelatin:water=5:95 mass ratio (gelatin concentration 5 mass%) was dissolved at a temperature of 60° C. The gelatin aqueous solution was coated on a polytetrafluoroethylene film (film thickness 50 μm) using a rod coater No. 20 manufactured by TP Giken Co., Ltd., and air-dried overnight at room temperature to obtain a gelatin film.

[0146] Next, gelatin made by Nitta Gelatin Co., Ltd. (gelatin strength 262g, raw material: alkali-treated cow bone) was used as gelatin, with a mass ratio of gelatin: water = 3:5 (gelatin concentration 37.5% by mass), and dissolved at a temperature of 60°C. The viscosity at 60°C was 960-970mPa·s. The gelatin aqueous solution was used as a spinning solution. Fig.23 The manufacturing device shown in the figure gathers gelatin fibers on a gelatin film arranged on a winding roller to form a nonwoven fabric, thereby manufacturing a laminate. The temperature of the spinning solution is 60°C, the nozzle diameter (inner diameter) is 250μm, the ejection pressure is 0.2MPa, the nozzle height is 5mm, the air pressure is 0.375MPa, the air temperature is 100°C, the distance between the fluid ejection port and the nozzle ejection port is 5mm, and the capture distance is 50cm. The laminate is air-dried at room temperature overnight, and then heated for dehydration and cross-linking. The cross-linking conditions are set to a temperature of 140°C and 48 hours.

[0147] The obtained laminate was punched into a cylinder with a diameter of 6 mm to produce a stent.

[0148] <Production of Cell Aggregates>

[0149] (1) The laminate (stent) obtained above was sterilized with ethylene oxide gas and then allowed to swell in Dulbecco's phosphate buffered saline (D-PBS(-)(1x), Nacalai Tesque) for 10 minutes. The diameter of the swollen laminate was 8 mm.

[0150] (2) After removing excess liquid from the swollen laminate with a pipette, the end was gripped with tweezers and set in one of the six wells of an IWAKI suspension culture microplate (without surface treatment) so that the gelatin membrane was in contact with the inner bottom surface of the well.

[0151] (3) Human fetal kidney cells HEK293 were cultured in liquid culture medium (Dulbecco's Modified Eagle's Medium, Sigma (10% fetal bovine serum, supplemented with 1% penicillin-streptomycin)) to a concentration of 2×10 7 The cell suspension was suspended in a manner of 10 cells / mL and 20 μL was dripped onto the surface of the gelatin nonwoven fabric of the laminate. The cells were cultured in an incubator at 37°C and 5% CO2 for 3 hours to allow the cells to adhere to the laminate. The cell seeding amount per unit area of ​​the scaffold was 6250 cells / mm 2 .

[0152] (4) Add 3 mL of the above liquid culture medium and culture in an incubator at 37°C and 5% CO2 for 72 hours.

[0153] (Example 2)

[0154] <Production of laminate (scaffold)>

[0155] The stacked body was prepared in the same manner as in Example 1 except that the nozzle diameter (inner diameter) was 150 μm, the nozzle discharge pressure was 0.275 MPa, the nozzle height was 5 mm, the air pressure was 0.375 MPa, the air temperature was 100°C, the distance between the fluid injection port and the nozzle discharge port was 5 mm, and the collection distance was 50 cm.

[0156] The obtained laminate was punched into a cylinder with a diameter of 6 mm and used as a stent.

[0157] <Production of Cell Aggregates>

[0158] A cell mass was prepared in the same manner as in Example 1 except that the laminate (scaffold) obtained above was used. The diameter of the swollen laminate was 8 mm.

[0159] (Example 3)

[0160] <Production of laminate (scaffold)>

[0161] The laminate obtained in the same manner as in Example 1 was punched into a cylinder having a diameter of 6 mm and used as a stent. The diameter of the laminate after swelling was 8 mm.

[0162] After the scaffold was immersed in a phosphate buffer containing fibronectin for 2 hours, the fibronectin solution was removed by suction. The phosphate buffer containing fibronectin was prepared by adding a fibronectin solution (1 mg / ml, Sigma) in a ratio of 1 / 100 (volume ratio) to Dulbecco's phosphate buffered saline (D-PBS(-)(1x), Nacalai Tesque).

[0163] <Production of Cell Aggregates>

[0164] A scaffold treated with fibronectin and iPS cell-derived cardiomyocytes (iCell (registered trademark) 2 , Fujifilm Wako Pure Chemical Industries, Ltd.) to reach 1×10 7 Cell suspension was obtained by suspending the cells in a liquid culture medium (iCell (registered trademark) cardiomyocyte thawing medium, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) at a concentration of 1 cells / mL, and adding a liquid culture medium (iCell (registered trademark) cardiomyocyte maintenance medium, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) after culturing for 4 hours. Cell aggregates were prepared in the same manner as in Example 1. The cell seeding amount per unit area of ​​the scaffold was 3125 cells / mm 2 .

[0165] (Example 4)

[0166] <Production of laminate (scaffold)>

[0167] The laminate obtained in the same manner as in Example 2 was punched into a cylinder having a diameter of 6 mm and used as a stent. The diameter of the laminate after swelling was 8 mm.

[0168] After the scaffold was immersed in a phosphate buffer containing fibronectin for 2 hours, the liquid culture medium containing fibronectin was removed by suction. The phosphate buffer containing fibronectin was obtained by adding a fibronectin solution (1 mg / mL, Sigma) in a manner that was 1 / 100 (volume ratio) relative to Dulbecco's phosphate buffered saline (D-PBS(-)(1x), Nacalai Tesque).

[0169] <Production of Cell Aggregates>

[0170] A scaffold treated with fibronectin and iPS cell-derived cardiomyocytes (iCell (registered trademark) 2 , Fujifilm Wako Pure Chemical Industries, Ltd.) to reach 1×10 7 Cell suspension was obtained by suspending the cells in a liquid culture medium (iCell (registered trademark) cardiomyocyte thawing medium, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) at a concentration of 1 cells / mL, and adding a liquid culture medium (iCell (registered trademark) cardiomyocyte maintenance medium, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) after culturing for 4 hours. Cell aggregates were prepared in the same manner as in Example 2. The cell seeding amount per unit area of ​​the scaffold was 3125 cells / mm 2 .

[0171] (Comparative Example 1)

[0172] Cell seeding and cell culture were carried out in the same manner as in Example 1 except that a 6-well IWAKI tissue culture microplate (for adherent cells) was used as the culture container.

[0173] (Comparative Example 2)

[0174] Cell seeding and cell culture were carried out in the same manner as in Example 3 except that a 6-well IWAKI tissue culture microplate (for adherent cells) was used as the culture container.

[0175] The results of various measurements and evaluations of the stents used in the Examples are shown in Table 1 below. Figure 1 and 2 The cross-sectional photographs of the stents used in Examples 1 and 2 are shown respectively. Figure 1 and Figure 2 It can be seen that the fiber intersections of the gelatin fibers constituting the gelatin non-woven fabric are at least partially melt-bonded, and the gelatin film and the gelatin fibers constituting the gelatin non-woven fabric are partially melt-bonded.

[0176] [Table 1]

[0177]

[0178] In Examples 1 to 2 and Comparative Example 1, the scaffolds were observed immediately after cell inoculation (hereinafter also referred to as "after inoculation"), after 3 hours of culture and addition of liquid culture medium (hereinafter also referred to as "after 3 hours of culture"), and after 72 hours of culture. The results are shown in Figures 3 to 5 , Fig. 9 and Table 2. In Examples 3 to 4 and Comparative Example 2, the scaffolds were observed immediately after cell inoculation (hereinafter also referred to as "after inoculation"), after culturing for 4 hours and adding liquid culture medium (hereinafter also referred to as "after culturing for 4 hours"), and after culturing for 72 hours. The results are shown in Figures 6 to 8 , Fig.10 and Table 3.

[0179] (1) Whether cells are detached

[0180] The ends of the scaffolds were observed at 4 times magnification using an optical microscope (Axio Vert. A1 manufactured by Zeiss) after seeding and 3 hours of culture (Examples 1 and 2) or 4 hours of culture (Examples 3 and 4).

[0181] (2) Fluorescence observation of living cells

[0182] A DMSO solution of bisbenzimide H33342 fluorochromium trihydrochloride (1 mg / mL, Nacalai Tesque) as a nuclear staining fluorescent reagent was added to the liquid culture medium at a concentration of 1 / 100 volume (v / v), and the culture medium was cultured at 37°C and 5% CO2 for 30 minutes, then washed with Dulbecco's phosphate buffered saline (D-PBS (-) (1x, Nacalai Tesque), and the liquid culture medium was added again.

[0183] Then, fluorescent observation of living cells was performed using a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation. In order to observe the front and back of the scaffold material separately, the ends of the scaffold material were clamped with tweezers and observed inverted. The observation images were taken at intervals of 10 μm in the thickness direction, and 50 images were overlapped by the maximum projection method (MIP). The overall image of the scaffold was connected to the 4-fold observation image. The magnified image is the 20-fold observation image. In the image, the part that appears white is the cell nucleus.

[0184] (3) Calculation of live cell count and live cell ratio

[0185] After the scaffold was inoculated for 1 day, it was washed with Dulbecco's phosphate buffered saline (D-PBS (-) (1x, Nacalai Tesque), and then transferred to a 15 mL centrifuge tube. 1 mL of 2.5 g / L trypsin / 1 mmol / L EDTA solution (Nacalai Tesque) was added dropwise. The scaffold was incubated at 37°C and 5% CO2 for 25 minutes. After visual confirmation that the scaffold was dissolved, the dead cells were stained with 0.5% trypan blue staining solution (Nacalai Tesque) and the cells were counted using an automatic cell counter (TC20 TM , Bio-Rad Laboratories) to calculate the number and proportion of live cells.

[0186] (4) Cell distribution within the scaffold

[0187] For the scaffolds cultured for 72 hours, a DMSO solution of bisbenzimide H33342 fluorochromium trihydrochloride (1 mg / mL, Nacalai Tesque) as a nuclear staining fluorescent reagent was added to the liquid culture medium at a concentration of 1 / 100 volume (v / v), and the scaffolds were cultured at 37°C and 5% CO2 for 30 minutes, then washed with Dulbecco's phosphate buffered saline (D-PBS (-) (1x, Nacalai Tesque), and the liquid culture medium was added again.

[0188] Then, the living cells were observed for fluorescence using a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation. In order to observe the front and back of the scaffold material separately, the ends of the scaffold material were clamped with tweezers and observed inverted. The observation was performed at intervals of 10 μm in the thickness direction, and the thickness of 0 μm (surface), 100 μm, and 200 μm were observed from the gelatin nonwoven fabric side and the gelatin film side, respectively, to study the distribution of cells in the depth direction.

[0189] Figure 3 These are the results (4 times) obtained by observing the ends of the scaffolds using an optical microscope in Example 1. (a) is the result after cell seeding, and (b) is the result when liquid culture medium was added after 3 hours of culture.

[0190] Figure 4 The whole image of the scaffold obtained by fluorescence observation of living cells (HEK293 cells) in the scaffold, (a) is the whole image of the scaffold after cell inoculation, (b) is the enlarged image of its center, (c) is the whole image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is the enlarged image of its center, (e) is the whole image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is the enlarged image of its center. Figure 4In (a), (c) and (e), the scale bar represents 1000 μm. Figure 4 In (b), (d) and (f), the scale bar represents 100 μm.

[0191] Figure 5 The whole image of the scaffold obtained by fluorescence observation of the living cells (HEK293 cells) in the scaffold in Example 2, (a) is the whole image of the scaffold after cell inoculation, (b) is the enlarged image of its central part, (c) is the whole image of the scaffold (cell aggregate) when the liquid culture medium is added after 3 hours of culture, (d) is the enlarged image of its central part, (e) is the whole image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is the enlarged image of its central part. Figure 5 In (a), (c) and (e), the scale bar represents 1000 μm. Figure 5 In (b), (d) and (f), the scale bar represents 100 μm.

[0192] Figure 6 These are the results (4 times) obtained by observing the ends of the scaffolds using an optical microscope in Example 3. (a) is the result after cell inoculation, and (b) is the result when liquid culture medium was added after 3 hours of culture.

[0193] Figure 7 The results of fluorescent observation of living cells (cardiomyocytes) in the scaffold in Example 3 are as follows: (a) is the overall image of the scaffold after cell inoculation, (b) is an enlarged image of its center, (c) is the overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its center, (e) is the overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its center. Figure 7 In (a), (c) and (e), the scale bar represents 1000 μm. Figure 7 In (b), (d) and (f), the scale bar represents 100 μm.

[0194] Figure 8 The results of fluorescent observation of living cells (cardiomyocytes) in the scaffold in Example 4 are as follows: (a) is the overall image of the scaffold after cell inoculation, (b) is an enlarged image of its center, (c) is the overall image of the scaffold (cell aggregate) when liquid culture medium is added after 3 hours of culture, (d) is an enlarged image of its center, (e) is the overall image of the scaffold (cell aggregate) after 72 hours of culture, and (f) is an enlarged image of its center. Figure 8 In (a), (c) and (e), the scale bar represents 1000 μm. Figure 8 In (b), (d) and (f), the scale bar represents 100 μm.

[0195] Depend on Figures 3 to 8 It can be seen that in Examples 1 to 4, there is almost no cell detachment from the scaffold after cell inoculation, at the stage of adding liquid culture medium after 3 hours (Examples 1 to 2) or 4 hours (Examples 3 to 4) of culture, and at any stage of 72 hours of culture, the inoculation efficiency is high, and culture can be carried out at a high density from the early stage of culture.

[0196] Fig. 9 The results (4 times) obtained by observing the cells at the ends of the stents for detachment using an optical microscope in Comparative Example 1 are as follows: (a) is the result after cell inoculation, and (b) is the result after adding liquid culture medium after 3 hours of culture. Fig. 9 It can be seen that in Comparative Example 1, a large number of cells fell off the scaffold immediately after cell seeding, and the seeding efficiency was low.

[0197] [Table 2]

[0198] Example 1 Example 2 Comparative Example 1 Number of living cells 39133.3 395333.3 250000.0 Inoculation efficiency (%) 97.8 98.8 62.5 Proportion of living cells (%) 96.5 94.5 98

[0199] From the data in Table 2, it can be seen that the inoculation efficiency in Comparative Example 1 was 62.5%, whereas the inoculation efficiency in Examples 1 and 2 was 97.8% or more, and the inoculation efficiency was significantly improved.

[0200] Fig.10 The results (4 times) obtained by observing the cells at the ends of the stents for detachment using an optical microscope in Comparative Example 2 are as follows: (a) is the result after cell inoculation, and (b) is the result after adding liquid culture medium after 4 hours of culture. Fig.10 It can be seen that in Comparative Example 2, a large number of cells fell off the scaffold after cell seeding, and the seeding efficiency was low.

[0201] [Table 3]

[0202] Example 3 Example 4 Comparative Example 2 Number of living cells 63466.7 95500.0 20950.0 Inoculation efficiency (%) 31.7 47.8 10.5 Proportion of living cells (%) 78.3 80.0 93

[0203] As can be seen from the data in Table 3, the seeding efficiency in Comparative Example 2 was 10.5%, while that in Example 3 was 31.7%, and that in Example 4 was 47.8%, which was significantly improved. The cell implantation rate of iPS-derived cardiomyocytes was low, and even when cultured on a cell-adhesive culture dish, the implantation rate was about 40 to 50%, and the seeding efficiency on the scaffold composed of the gelatin nonwoven fabric and gelatin membrane was excellent.

[0204] Fig.11The results are obtained by observing the distribution of living cells in the scaffold after culturing for 72 hours in Example 1. (a) is the result of observing the surface of the gelatin nonwoven fabric side, (b) is the result of observing the position 100 μm away from the gelatin nonwoven fabric surface in the thickness direction, (c) is the result of observing the position 200 μm away from the gelatin nonwoven fabric surface in the thickness direction, (d) is the result of observing the position 200 μm away from the gelatin film surface in the thickness direction, (e) is the result of observing the position 100 μm away from the gelatin film surface in the thickness direction, and (f) is the result of observing the surface of the gelatin film side. Fig.11 In the figure, the scale bar indicates 500 μm.

[0205] Fig.12 The following are photographs showing the distribution of living cells in the scaffold after culturing for 72 hours in Example 2. (a) is the result obtained by observing the surface of the gelatin nonwoven fabric side, (b) is the result obtained by observing a portion 100 μm away from the gelatin nonwoven fabric surface in the thickness direction, (c) is the result obtained by observing a portion 200 μm away from the gelatin nonwoven fabric surface in the thickness direction, (d) is the result obtained by observing a portion 200 μm away from the gelatin film surface in the thickness direction, (e) is the result obtained by observing a portion 100 μm away from the gelatin film surface in the thickness direction, and (f) is the result obtained by observing the surface of the gelatin film side. Fig.12 In the figure, the scale bar indicates 500 μm.

[0206] Depend on Fig.11 and 12 It can be seen that in the embodiment, the cells also invaded the inside of the scaffold and were cultured in three dimensions. In the case of Example 1, in which the average fiber diameter of the gelatin fibers constituting the gelatin nonwoven fabric is large (the pore diameter of the gelatin nonwoven fabric is large), there are fewer cells on the gelatin nonwoven fabric side, and the closer to the gelatin membrane side along the thickness direction, the more cells there are. In contrast, in the case of Example 2, in which the average fiber diameter of the gelatin fibers constituting the gelatin nonwoven fabric is small (the pore diameter of the gelatin nonwoven fabric is small), there are more cells on the gelatin nonwoven fabric side than on the gelatin membrane side.

[0207] (Example 5)

[0208] <Evaluation 1 of Compounds Using iPS Cell-Derived Cardiomyocytes>

[0209] (1) Evaluation of synchronous beating of cardiomyocytes

[0210] Cells were seeded in the same manner as in Example 4, and liquid culture medium was added 4 hours later for cell culture. On the 4th day of culture, 5 / 100 (volume ratio) of calcium indicator (EarlyTox Cardiotoxicity Kit, Molecular Devices) was added to the culture medium to perform fluorescent staining of calcium ions in cardiomyocytes.

[0211] Movies were captured at 20 FPS using a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation. Colored areas were identified from the resulting movies using an image analysis device, CellPathfinder manufactured by Yokogawa Electric Corporation, and the fluorescence intensity was plotted against time to obtain the signal waveform of calcium ions in cardiomyocytes.

[0212] Fig.13 The results of imaging evaluation of intracellular calcium ions in a cell aggregate after the addition of a calcium indicator on the fourth day of culture, (a) is a bright field image, (b) is an image obtained by fluorescence observation of intracellular calcium ions 120 minutes after the addition of the calcium indicator, (c) is an image obtained by fluorescence observation of intracellular calcium ions 0.7 seconds after the time point of (b), and (d) is a graph in which the fluorescence intensity of measurement points A and B is plotted against time. The distance between measurement points A and B is 3145 μm.

[0213] Depend on Fig.13 As shown in (b) to (d), the intracellular calcium ion concentration of cardiomyocytes cultured on a scaffold composed of gelatin nonwoven fabric and gelatin membrane changes at the same time point even in a wide range of more than 3 mm, and the cells beat synchronously.

[0214] (2) Evaluation of responsiveness to isoproterenol

[0215] As described above, 5 / 100 (mass ratio) of calcium indicator was added to the culture medium, and after culturing for 2 hours, calcium ions in the cardiomyocytes were observed by fluorescence staining. After observation, as a compound that accelerates myocardial pulsation, isoproterenol, a β-stimulant used in the treatment of bradycardia, atrioventricular block, and bronchial asthma, was added to the liquid culture medium to reach 100 nM, and after 5 minutes, calcium ions in the cardiomyocytes were observed by fluorescence staining.

[0216] Fig.14 The results show the responsiveness to isoproterenol on the 4th day of culture in Example 5. The addition of 100 nM isoproterenol accelerated the change in intracellular calcium ion concentration, and the beat frequency changed from 60 bpm before the addition to 76 bpm after the addition.

[0217] From the above, it can be seen that by comparing the beat rate of cardiomyocytes and / or the peak shape of fluorescence intensity over time before and after contacting the target compound with the cell mass, the effect of the compound on the cardiomyocytes can be determined.

[0218] (Example 6)

[0219] <Evaluation 2 of compounds using iPS cell-derived cardiomyocytes>

[0220] (1) Evaluation of synchronous beating of cardiomyocytes

[0221] Use a cell number of 2 × 10 7 Cell suspension was obtained by suspending the cells in the manner of cells / mL. Cell inoculation was performed in the same manner as in Example 4, and liquid culture medium was added 4 hours later for cell culture. After the 4th day of culture, 5 / 100 (volume ratio) of calcium indicator (EarlyTox Cardiotoxicity Kit, Molecular Device) was added to the culture medium to perform fluorescent staining of calcium ions in cardiomyocytes. The cell inoculation amount per unit area of ​​the scaffold was 6250 cells / mm 2 .

[0222] Movies were captured at 20 FPS using a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation. Colored areas were identified from the resulting movies using an image analysis device, CellPathfinder manufactured by Yokogawa Electric Corporation, and the fluorescence intensity was plotted against time to obtain the signal waveform of calcium ions in cardiomyocytes.

[0223] Fig.15 The results of imaging evaluation of intracellular calcium ions in a cell aggregate after addition of a calcium indicator on the fourth day of culture are shown in (a), a bright field image, (b) an image obtained by fluorescence observation of intracellular calcium ions 120 minutes after addition of the calcium indicator, (c) an image obtained by fluorescence observation of intracellular calcium ions 0.7 seconds after the time point of (b), and (d) a graph in which the fluorescence intensity of measurement points A and B is plotted against time. The distance between measurement points A and B is 2465 μm.

[0224] Depend on Fig.15 As shown in (b) to (d), the intracellular calcium ion concentration of cardiomyocytes cultured on a scaffold composed of a cell assembly, i.e., gelatin nonwoven fabric and gelatin membrane, changes at the same time point and beats synchronously even in a wide range of more than 2 mm.

[0225] (2) Evaluation of responsiveness to arrhythmia-inducing compounds

[0226] In the same manner as above, a calcium indicator was added to the culture medium at 5 / 100 (volume ratio), and after culturing for 2 hours, calcium ions in the cardiomyocytes were observed by fluorescence. Then, as a compound inducing arrhythmia, an inhibitor of delayed rectifier potassium current (Ikr), E-4031 (Fujifilm Wako Pure Chemical Industries, Ltd.), was added to the liquid culture medium at 900 nM, and fluorescence observation was performed 120 minutes after addition.

[0227] Fig.16 The results show the responsiveness to E-4031 on the fourth day of culture. (a) is an image obtained by fluorescence observation of calcium ions in cells 120 minutes after the addition of E-4031, (b) is an image obtained by fluorescence observation of calcium ions in cells 0.4 seconds after the time point of (a), and (c) is a graph in which the fluorescence intensity of measurement point A and measurement point B is plotted against time.

[0228] Depend on Fig.16 (a) to (c) show that when E-4031 is added to cardiomyocytes cultured on a scaffold composed of a cell assembly, i.e., gelatin nonwoven fabric and gelatin membrane, the intracellular calcium ion concentration changes at different time points depending on the site, and the synchronous beating is inhibited. Fig.16 (c) At measurement point B, the pulsation behavior significantly changed compared to measurement point A, and arrhythmia was confirmed.

[0229] (Example 7)

[0230] <Evaluation 3 of Compounds Using iPS Cell-Derived Cardiomyocytes>

[0231] (1) Preparation of cardiomyocyte aggregates

[0232] The seeding rate per unit area of ​​the scaffold reached 6000 cells / mm 2 Cell inoculation and culture were performed in the same manner as in Example 6, except that the cells were inoculated in the manner of .

[0233] (2) Structural observation of cardiomyocyte assemblies

[0234] On the 3rd and 7th day of culture, the scaffolds containing cardiomyocytes (cardiomyocyte aggregates) were collected and fixed with 16% paraformaldehyde, and then fluorescently stained. The nuclei were stained with a DMSO solution of bisbenzimide H33342 fluorochromium trihydrochloride (1 mg / mL, Nacalai Tesque Co., Ltd.), and the fluorescence was stained with Alexa Fluor TMActin filaments were stained with 568 phalloidin (Invitrogen), and α-actin was immunostained using anti-α-actin (Sarcomeric) antibody (Sigma) as a primary antibody for structural observation.

[0235] (3) Evaluation of compound responsiveness in cardiomyocyte assemblies using calcium imaging

[0236] On the sixth day of culture, the cardiomyocyte aggregate was placed with the side with a large number of cells facing the bottom of the culture dish (IWAKI suspension culture microplate (no surface treatment) 6-well) and left to stand for 1 day. On the seventh day of culture, 25 / 100 (volume ratio) of calcium indicator (EarlyTox Cardiotoxicity Kit, Molecular Device) was added to the culture medium to perform fluorescent staining of calcium ions in the cardiomyocytes.

[0237] The compounds shown in Table 4 below are respectively cumulatively administered to the target concentration, and the compound responsiveness is observed according to the change in the concentration of calcium ions. After 10 minutes of administering the compound at each concentration, a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation is used to shoot fluorescence delayed images at 20fps. According to the obtained image, the image analysis device CellPathfinder manufactured by Yokogawa Electric Corporation is used to plot the fluorescence intensity of the entire 10-fold field of view relative to time, thereby obtaining the signal waveform of calcium ions in cardiomyocytes. Verapamil is a Ca channel antagonist with ICr inhibitory effect.

[0238] (4) Evaluation of the contractile force of cardiomyocyte assemblies

[0239] For each sample in which the responsiveness of the compounds in Table 4 was observed by the above-mentioned calcium ion indicator, a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation was used to capture bright field images at 20 fps. The contractile force and contraction and relaxation velocity of the myocardial cell assembly were evaluated on the obtained images using the ImageJ plug-in tool MUSCLEMOTION (Sala et al, Circu. Res., 2018).

[0240] [Table 4]

[0241]

[0242] Fig.17The fluorescence staining results of the cardiomyocyte aggregates in Example 7. (a) is a staining image of the nucleus and actin filaments on the 3rd day of culture, (b) is an immunostaining image of α-actin on the 3rd day of culture, and (c) is a partial enlarged image of (b). (d) is a staining image of the nucleus and actin filaments on the 7th day of culture, (e) is an immunostaining image of α-actin on the 7th day of culture, and (f) is a partial enlarged image of (e). Fig.17 In the figure, the scale bar indicates 50 μm.

[0243] Depend on Fig.17 The results of phalloidin staining in (a) show that in the cardiomyocyte assembly, in the short-term culture period of the third day of culture, actin filaments exist in a manner that covers the gelatin fibers constituting the scaffold and are connected over a wide range. Fig.17 The results of α-actin immunostaining in (b) and (c) show that the sarcomere structure (striped pattern) constituting the cardiomyocytes is expressed and oriented along the length direction of the gelatin fibers. In addition, on the 7th day of culture, the sarcomere structure develops more coarsely, and the orientation of the gelatin fibers in the length direction becomes clearer. It is known that the sarcomere structure of cardiomyocytes is oriented in one direction in mature cardiomyocytes, and cardiomyocyte aggregates can orient iPS cell-derived cardiomyocytes in advance to obtain structurally mature cardiomyocytes. In addition, since the sarcomere length within the sarcomere structure is about 2 μm, which is the same as the sarcomere length of mature myocardium, it can be seen that the cardiomyocytes are mature.

[0244] Fig.18 Graphs showing the responsiveness to each compound in Example 7. (a) is a signal waveform of calcium ion before and after administration of isoproterenol at 1000 nM, and (b) is the pulse rate at each concentration of isoproterenol. (c) is a signal waveform of calcium ion before and after administration of E-4031 at 1000 nM, and (d) is the pulse rate at each concentration of E-4031. (e) is a signal waveform of calcium ion before and after administration of verapamil at 1000 nM, and (f) is the pulse rate at each concentration of verapamil.

[0245] Depend on Fig.18 It can be seen that myocardial cell assemblies show different responsiveness to compounds with different effects. When isoproterenol was given, the signal waveform of calcium ions became sharper (a) and the heart rate became faster (b) compared with before. When E-4031 was given, the signal waveform of calcium ions was elongated (c) and the heart rate was reduced compared with before, and arrhythmia occurred above 100nM (d). When verapamil was given, the signal waveform of calcium ions became smaller (e) compared with before, and the heart rate increased (f).

[0246] Fig.19The graphs are graphs showing the responsiveness to each compound in Example 7. (a) shows the contractile force before and after administration of isoproterenol at 1000 nM, and (b) shows the contraction and relaxation velocity before and after administration of isoproterenol at 1000 nM. (c) shows the contractile force before and after administration of E-4031 at 1000 nM, and (d) shows the contraction and relaxation velocity before and after administration of E-4031 at 1000 nM. (e) shows the contractile force before and after administration of verapamil at 1000 nM, and (f) shows the contraction and relaxation velocity before and after administration of verapamil at 1000 nM.

[0247] Depend on Fig.19 It can be seen that the cardiomyocyte aggregates show different changes in contractility and contraction and relaxation speed to compounds with different effects, and the responsiveness of the compounds is easily evaluated. When isoproterenol is given, the contractility increases (a) and the contraction and relaxation speed also increases (b) compared to before the administration. When E-4031 is given, the contractility decreases (c) and the contraction and relaxation speed also decreases (d) compared to before the administration. When verapamil is given, the contractility decreases (e) and the contraction and relaxation speed also decreases (f) compared to before the administration. By adding the beta receptor stimulator isoproterenol, the contractility increases (positive inotropic effect is confirmed), which shows that the cardiomyocytes in the cardiomyocyte aggregate are mature.

[0248] (Example 8)

[0249] <Evaluation 4 of compounds using iPS cell-derived cardiomyocytes>

[0250] (1) Preparation of cardiomyocyte aggregates

[0251] The seeding rate per unit area of ​​the scaffold reached 8000 cells / mm 2 Cell inoculation and culture were performed in the same manner as in Example 7, except that the cells were inoculated in the manner of .

[0252] (2) Evaluation of compound responsiveness in cardiomyocyte assemblies using calcium imaging

[0253] Fluorescence staining of calcium ions in cardiomyocytes was performed in the same manner as in Example 7 except that the cardiomyocyte aggregates were arranged with the surface with a large number of cells facing the bottom of the culture dish one day before the addition of the calcium indicator and the calcium indicator was added on the 6th to 10th day of culture.

[0254] The compounds shown in Table 5 below (used as therapeutic drugs for COVID-19) were cumulatively administered to a target concentration, and the signal waveform of calcium ions in cardiomyocytes was obtained in the same manner as in Example 7.

[0255] (3) Evaluation of the contractile force of cardiomyocyte assemblies

[0256] The contractile force of the myocardial aggregate was evaluated in the same manner as in Example 7 for each sample in which the responsiveness of the compounds shown in Table 5 below was observed using the above-mentioned calcium ion indicator.

[0257] [Table 5]

[0258]

[0259] Fig. 20 The graphs show the responsiveness (signal waveform of calcium ions) to each compound in Example 8. (a) shows azithromycin, (b) shows chloroquine, (c) shows hydroxychloroquine, (d) shows the results when azithromycin (3 μM) and chloroquine are used in combination, and (e) shows the results when azithromycin (3 μM) and hydroxychloroquine are used in combination.

[0260] The probability of samples showing arrhythmic calcium ion signal waveforms when the compounds described in Table 5 above were used in Example 8 is shown in Table 6 below.

[0261] [Table 6]

[0262]

[0263] Depend on Fig. 20 As shown in Table 6, the risk of arrhythmia is high for chloroquine and hydroxychloroquine, while the risk of arrhythmia is reduced when azithromycin is used in combination with chloroquine or hydroxychloroquine.

[0264] Fig.21 The graphs show the responsiveness (contractile force) when each compound was used in Example 8. (a) shows azithromycin, (b) shows chloroquine, (c) shows hydroxychloroquine, (d) shows the results of the combined use of azithromycin (3 μM) and chloroquine, and (e) shows the results of the combined use of azithromycin (3 μM) and hydroxychloroquine.

[0265] The following Table 7 shows the probability of specimens having contractile force reduced by half compared to before compound administration at each concentration of the compound described in Table 5 in Example 8.

[0266] [Table 7]

[0267]

[0268] Depend on Fig.21 As shown in Table 7, when azithromycin is used in combination with chloroquine or hydroxychloroquine, the contractile force decreases at low concentrations, and the risk of developing cardiac contraction disorder increases, compared with chloroquine or hydroxychloroquine alone.

[0269] (Example 9)

[0270] <Evaluation 5 of Compounds Using iPS Cell-Derived Cardiomyocytes>

[0271] (1) Preparation of cardiomyocyte aggregates

[0272] As iPS cell-derived cardiomyocytes, Pluriciyte (registered trademark) manufactured by Ncardia Corporation was used, and the seeding density per unit area of ​​the scaffold was 6000 cells / mm. 2 Cell inoculation and culture were performed in the same manner as in Example 3, except that the cells were inoculated in the manner of .

[0273] (2) Evaluation of compound responsiveness of cardiomyocyte assemblies using membrane potential indicators

[0274] On the 7th day of culture, the cardiomyocyte aggregate was set up with the side with a large number of cells facing the bottom of the culture dish (IWAKI suspension culture microplate (no surface treatment) 6-well) and left to stand for 1 day. On the 8th day of culture, a membrane potential indicator (FluoVolt, Invitrogen) was added to the culture medium, incubated at 37°C for 30 minutes, and the membrane potential in the cardiomyocytes was measured by fluorescent staining.

[0275] E-4031 was cumulatively administered to the culture solution in a manner reaching 0, 1, 10, 100, 1000 nM, and the responsiveness was observed according to the change in membrane potential. After 10 minutes of administration of the compound at each concentration, a confocal imaging device (CQ1) manufactured by Yokogawa Electric Corporation was used to capture fluorescence delayed images at 20 fps. Based on the obtained images, the fluorescence intensity of the entire field of view of x10 was plotted against time using the image analysis device CellPathfinder manufactured by Yokogawa Electric Corporation, thereby obtaining the signal waveform of the membrane potential in the cardiomyocyte.

[0276] Fig. 22 The results of the compound responsiveness observed by the membrane potential indicator in Example 9 are shown in FIG. Fig. 22 It was found that even in the case of a change in membrane potential caused by a membrane potential indicator, the addition of E-4031 caused an arrhythmic waveform to occur, and thus arrhythmia could be evaluated.

[0277] From the above, it can be seen that by comparing the signal waveforms of calcium ions, contractile force, membrane potential, etc. in the myocardial cells before and after the target compound is brought into contact with the cell aggregate, it is possible to determine the effect of the compound on the myocardial cells, such as whether it has cardiotoxicity.

[0278] As can be seen from the above, in one or more embodiments of the present invention, cell assemblies can be used in methods for evaluating various properties of compounds, such as metabolism, pharmacological action, and toxic action.

[0279] The present invention is not particularly limited, but preferably includes the following aspects.

[0280] [1] A cell assembly comprising cells and a scaffold, wherein the scaffold is composed of a laminate, wherein the laminate comprises a gelatin nonwoven fabric containing gelatin as a main component and a gelatin film containing gelatin as a main component laminated on one surface of the gelatin nonwoven fabric,

[0281] The cells are present on at least one of a surface and an interior of the gelatin nonwoven fabric.

[0282] [2] The cell aggregate according to [1], wherein

[0283] The average fiber diameter of the swollen gelatin fibers constituting the gelatin nonwoven fabric is 2 μm or more and 400 μm or less, and the fiber intersections are at least partially melt-bonded, and the gelatin film is partially melt-bonded to the gelatin fibers constituting the gelatin nonwoven fabric.

[0284] [3] The cell aggregate according to [1] or [2], wherein

[0285] The gelatin nonwoven fabric has a thickness of 0.1 mm to 2.0 mm, and a weight per unit area of ​​10 g / m 2 Above and 600g / m 2 the following.

[0286] [4] The cell assembly according to any one of [1] to [3], wherein

[0287] The gelatin film has a thickness of 0.80 μm or more and 3.20 μm or less.

[0288] [5] The cell assembly according to any one of [1] to [4], wherein

[0289] The ratio Tf / Tn of the thickness Tn of the gelatin nonwoven fabric to the thickness Tf of the gelatin film is 7.5×10 -3 the following.

[0290] [6] The cell assembly according to any one of [1] to [5], wherein

[0291] The gelatin nonwoven fabric and the gelatin film are cross-linked by thermal dehydration.

[0292] [7] The cell assembly according to any one of [1] to [6], wherein

[0293] The cells exist both on the surface and inside of the gelatin nonwoven fabric.

[0294] [8] The cell assembly according to any one of [1] to [7], wherein

[0295] The cells are one or more selected from stem cells, cancer cells, myocardial cells, neurons, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from stem cells, and myocardial cells, neurons, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from organisms.

[0296] [9] The cell assembly according to any one of [1] to [8], wherein

[0297] The cells include mature cardiomyocytes, which are cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells.

[0298]

[10] The method for producing a cell assembly according to any one of [1] to [9], comprising the following steps:

[0299] A step of preparing a scaffold composed of a laminate and a culture container whose inner surface is not hydrophilized, wherein the laminate comprises a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric;

[0300] A step of arranging the swollen scaffold in a culture container whose inner surface is in a dry state so that the gelatin film side contacts the inner bottom surface of the culture container; and

[0301] The process of dropping a cell suspension onto the gelatin nonwoven fabric of the scaffold and culturing the cells.

[0302]

[11] The method for producing a cell aggregate according to

[10] , wherein:

[0303] The cell suspension was dropped onto the gelatin nonwoven fabric of the scaffold and allowed to stand for a specified period of time, and then a liquid culture medium was added for cell culture.

[0304]

[12] The method for producing a cell aggregate according to

[10] or

[11] , wherein:

[0305] The cell suspension contains cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells, and the cardiomyocytes are matured by culturing the cells for a predetermined period of time.

[0306]

[13] The kit for preparing a cell assembly according to any one of [1] to [9], wherein

[0307] The preparation kit comprises a support composed of a laminate and a culture container whose inner surface is not hydrophilized, wherein the laminate comprises a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric;

[0308] When preparing the cell aggregate, the swollen scaffold is placed in a culture container whose inner surface is dry so that the gelatin membrane side contacts the inner bottom surface of the culture container, and the cell suspension is dropped onto the gelatin nonwoven fabric of the scaffold.

[0309]

[14] The cell aggregate preparation kit according to

[13] , wherein

[0310] The cell suspension contains cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells, and the kit is used for preparing mature cardiomyocytes.

[0311]

[15] A method for evaluating a compound for evaluating a property of a compound, comprising:

[0312] a step of contacting a compound with the cell assembly of any one of [1] to [9]; and

[0313] A step of determining whether the physiological properties of a cell assembly are altered by contact with a compound.

[0314]

[16] The method for evaluating a compound according to

[15] , wherein:

[0315] The property of the compound is one or more selected from metabolism, pharmacological action and toxic action.

[0316]

[17] The method for evaluating a compound according to

[15] or

[16] , wherein:

[0317] The cell assembly comprises cardiomyocytes,

[0318] The determination step is performed by one or more selected from the group consisting of imaging of intracellular calcium ions, imaging of intracellular membrane potential, and evaluation of contractile force of cell aggregates.

[0319] Explanation of symbols

[0320] 1 Heating tank

[0321] 2 Spinning solution

[0322] 3 Nozzle outlet

[0323] 4.6 Compressor

[0324] 5 Fluid injection port

[0325] 7 Pressure fluid

[0326] 8 Gelatin Fiber

[0327] 9 Gelatin non-woven fabric

[0328] 10 Gelatin film

[0329] 11 Take-up roller

[0330] 12 Insulated container

[0331] 20 Manufacturing equipment

Claims

1. A cell aggregate, characterized in that: Contains cells and scaffolds, The stent is composed of a laminated body, wherein the laminated body includes a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric. The gelatin film is partially melt-bonded to the gelatin fibers constituting the gelatin non-woven fabric, thereby integrating the gelatin non-woven fabric with the gelatin film. The gelatin nonwoven fabric has a thickness of 0.1 mm or more and 2.0 mm or less. The gelatin film has a thickness of 0.5 μm or more and 10 μm or less. The unit area weight of the gelatin nonwoven fabric is 10 g / m 2 Above and 600g / m 2 the following The cells are present on at least one of the surface and the interior of the gelatin nonwoven fabric, The gelatin film is in contact with the culture container, and the cells are not in direct contact with the culture container.

2. The cell aggregate according to claim 1, wherein The average fiber diameter of the swollen gelatin fibers constituting the gelatin nonwoven fabric is 2 μm or more and 400 μm or less, and the fiber intersections are at least partially melt-bonded.

3. The cell aggregate according to claim 1 or 2, wherein The gelatin film has a thickness of 0.80 μm or more and 3.20 μm or less.

4. The cell aggregate according to claim 1 or 2, wherein The ratio Tf / Tn of the thickness Tn of the gelatin nonwoven fabric to the thickness Tf of the gelatin film is 7.5×10 -3 the following.

5. The cell aggregate according to claim 1 or 2, wherein The gelatin nonwoven fabric and the gelatin film are cross-linked by thermal dehydration.

6. The cell aggregate according to claim 1 or 2, wherein The cells exist both on the surface and inside of the gelatin nonwoven fabric.

7. The cell aggregate according to claim 1 or 2, wherein The cells are one or more selected from stem cells, cancer cells, myocardial cells, neurons, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from stem cells, and myocardial cells, neurons, hepatocytes, fibroblasts, endothelial cells and epithelial cells derived from organisms.

8. The cell aggregate according to claim 1 or 2, wherein The cells include mature cardiomyocytes, which are cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells.

9. The cell aggregate according to claim 1 or 2, wherein The inner surface of the culture container is not subjected to hydrophilic treatment.

10. The method for producing a cell assembly according to any one of claims 1 to 9, wherein: The process includes the following steps: A step of preparing a scaffold composed of a laminate and a culture container whose inner surface is not hydrophilized, wherein the laminate comprises a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric; A step of arranging the swollen scaffold in a culture container whose inner surface is in a dry state so that the gelatin film side contacts the inner bottom surface of the culture container; and The process of dropping a cell suspension onto the gelatin nonwoven fabric of the scaffold and culturing the cells.

11. The method for producing a cell assembly according to claim 10, wherein: The cell suspension was dropped onto the gelatin nonwoven fabric of the scaffold and allowed to stand for a specified period of time, and then a liquid culture medium was added for cell culture.

12. The method for producing a cell assembly according to claim 10 or 11, wherein: The cell suspension contains cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells, and the cardiomyocytes are matured by culturing the cells for a predetermined period of time.

13. The cell assembly preparation kit according to any one of claims 1 to 9, wherein The preparation kit comprises a support composed of a laminate and a culture container whose inner surface is not hydrophilized, wherein the laminate comprises a gelatin nonwoven fabric mainly composed of gelatin and a gelatin film mainly composed of gelatin laminated on one surface of the gelatin nonwoven fabric; When preparing the cell aggregate, the swollen scaffold is placed in a culture container whose inner surface is dry so that the gelatin membrane side contacts the inner bottom surface of the culture container, and the cell suspension is dropped onto the gelatin nonwoven fabric of the scaffold.

14. The cell assembly preparation kit according to claim 13, wherein: The cell suspension contains cardiomyocytes differentiated from stem cells or cardiomyocytes differentiated from somatic cells, and the kit is used for preparing mature cardiomyocytes.

15. A method for evaluating a compound for evaluating a property of the compound, comprising: A step of contacting a compound with the cell assembly according to any one of claims 1 to 9; and A step of determining whether the physiological properties of a cell assembly are altered by contact with a compound.

16. The method for evaluating a compound according to claim 15, wherein: The property of the compound is one or more selected from metabolism, pharmacological action and toxic action.

17. The method for evaluating a compound according to claim 15 or 16, wherein: The cell assembly comprises cardiomyocytes, The determination step is performed by one or more selected from the group consisting of imaging of intracellular calcium ions, imaging of intracellular membrane potential, and evaluation of contractile force of cell aggregates.